UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 18, 2007
Bionovo, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 000-50073 | 87-0576481 |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| | |
5858 Horton Street, Suite 375 Emeryville, California | 94608 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (510) 601-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
CURRENT REPORT ON FORM 8-K
BIONOVO, INC.
April 19, 2007
Item 8.01. Other Events.
On April 18, 2007, Bionovo, Inc. issued a press release announcing the initiation of its multi-center Phase 1/2 clinical trial of BZL101, its drug candidate for the treatment of women with advanced breast cancer. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
Exhibit No. | Description |
| 99.1 | Press Release issued by Bionovo, Inc. on April 18, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
| | BIONOVO, INC. |
|
|
|
| Date: April 19, 2007 | By: | /s/ James P. Stapleton |
| |
James P. Stapleton |
| | Chief Financial Officer |
